Search Results - "Weerakkody, Govinda J."

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial by Nicholls, Stephen J., MBBS, PhD, Lincoff, A. Michael, MD, Barter, Philip J., MBBS, PhD, Brewer, H. Bryan, MD, Fox, Keith A.A., MBChB, F MedSci, Gibson, C. Michael, MD, Grainger, Christopher, MD, Menon, Venugopal, MD, Montalescot, Gilles, MD, Rader, Daniel, MD, Tall, Alan R., MBBS, McErlean, Ellen, MSN, Riesmeyer, Jeffrey, MD, Vangerow, Burkhard, MD, Ruotolo, Giacomo, MD, PhD, Weerakkody, Govinda J., PhD, Nissen, Steven E., MD

“…Background Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein…”
Get full text

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel by Small, David S., Farid, Nagy A., Payne, Christopher D., Weerakkody, Govinda J., Li, Ying G., Brandt, John T., Salazar, Daniel E., Winters, Kenneth J.

“…Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active metabolite that inhibits the platelet P2Y12 ADP receptor. In this…”
Get full text

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program by Nicholls, Stephen J, Tofé, Santiago, le Roux, Carel W, D'Alessio, David A, Wiese, Russell J, Pavo, Imre, Brown, Katelyn, Weerakkody, Govinda J, Zeytinoglu, Meltem, Romera, Irene C

“…Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal…”
Get full text

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes by McGuire, Darren K., D’Alessio, David, Nicholls, Stephen J., Nissen, Steven E., Riesmeyer, Jeffrey S., Pavo, Imre, Sethuraman, Shanthi, Heilmann, Cory R., Kaiser, John J., Weerakkody, Govinda J.

“…Abstract Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to…”
Get full text

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis by Sattar, Naveed, McGuire, Darren K., Pavo, Imre, Weerakkody, Govinda J., Nishiyama, Hiroshi, Wiese, Russell J., Zoungas, Sophia

“…Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its…”
Get full text

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy by Riesmeyer, Jeffrey S., Salazar, Daniel E., Weerakkody, Govinda J., Ni, Lan, Wrishko, Rebecca E., Ernest II, C. Steven, Luo, Junxiang, Li, Ying G., Small, David S., Rohatagi, Shashank, Macias, William L.

“…In TRITON-TIMI 38, levels of the prasugrel active metabolite (pras-AM) were measured in a population pharmacokinetic substudy that characterized the intrinsic…”
Get full text

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis by Goodnough, Lawrence T., MD, Smith, Peter K., MD, Levy, Jerrold H., MD, Poston, Robert S., MD, Short, Mary A., MSN, Weerakkody, Govinda J., PhD, LeNarz, LeRoy A., MD

“…Objective Coronary artery bypass grafting-related bleeding and associated transfusion is a concern with dual antiplatelet therapy in patients with acute…”
Get full text

Comparison of Speed of Onset of Platelet Inhibition After Loading Doses of Clopidogrel Versus Prasugrel in Healthy Volunteers and Correlation With Responder Status by Weerakkody, Govinda J., PhD, Jakubowski, Joseph A., PhD, Brandt, John T., MD, Farid, Nagy A., PhD, Payne, Christopher D., MS, Zhu, Jianyu, MS, Warner, Margaret R., PhD, DVM, Naganuma, Hideo, PhD, Winters, Kenneth J., MD

“…Failure to achieve an adequate level of platelet inhibition during percutaneous coronary intervention is associated with an increased risk for periprocedural…”
Get full text

Stereoselective Metabolism of Prasugrel in Humans Using a Novel Chiral Liquid Chromatography-Tandem Mass Spectrometry Method by Wickremsinhe, Enaksha R, Tian, Ye, Ruterbories, Kenneth J, Verburg, Elizabeth M, Weerakkody, Govinda J, Kurihara, Atsushi, Farid, Nagy A

“…A liquid chromatography-tandem mass spectrometry method was developed to chromatographically separate the four stereoisomers of the active metabolite of…”
Get full text

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects by Jakubowski, Joseph A., Payne, Christopher D., Brandt, John T., Weerakkody, Govinda J., Farid, Nagy A., Small, David S., Naganuma, Hideo, Li, Grace Ying, Winters, Kenneth J.

“…Prasugrel (CS-747, LY640315), a novel thienopyridine, is a potent and orally active antiplatelet agent in vivo. The aims of this double-blind, double-dummy,…”
Get full text

Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity by Zile, Michael R., Borlaug, Barry A., Kramer, Christopher M., Baum, Seth J., Litwin, Sheldon E., Menon, Venu, Ou, Yang, Weerakkody, Govinda J., Hurt, Karla C., Kanu, Chisom, Murakami, Masahiro, Packer, Milton

“…Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of…”
Get full text

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity by Packer, Milton, Zile, Michael R., Kramer, Christopher M., Baum, Seth J., Litwin, Sheldon E., Menon, Venu, Ge, Junbo, Weerakkody, Govinda J., Ou, Yang, Bunck, Mathijs C., Hurt, Karla C., Murakami, Masahiro, Borlaug, Barry A.

“…Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic…”
Get full text

Mortality Benefit With Prasugrel in the TRITON―TIMI 38 Coronary Artery Bypass Grafting Cohort: Risk-Adjusted Retrospective Data Analysis by SMITH, Peter K, GOODNOUGH, Lawrence T, LEVY, Jerrold H, POSTON, Robert S, SHORT, Mary A, WEERAKKODY, Govinda J, LENARZ, Leroy A

“…The objective of this study was to characterize the bleeding, transfusion, and other outcomes of patients related to the timing of prasugrel or clopidogrel…”
Get full text

90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials by ROSENSTOCK, JULIO, DEL PRATO, STEFANO, FRANCO, DENISE R., VÁZQUEZ, LUIS A., DAI, BIYUE, WEERAKKODY, GOVINDA J., FERNANDEZ LANDO, LAURA, RODRÍGUEZ, ÁNGEL, BERGMAN, BRANDON

“…Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, demonstrated clinically meaningful improvements in glycemic control with 23% to 62% of patients achieving…”
Get full text

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38 by Wrishko, Rebecca E., Ernest II, C. Steven, Small, David S., Li, Ying G., Weerakkody, Govinda J., Riesmeyer, Jeffrey R., Macias, William L., Rohatagi, Shashank, Salazar, Daniel E., Antman, Elliott M., Wiviott, Stephen D., Braunwald, Eugene, Ni, Lan

“…Serial pharmacokinetic (PK) sampling in 1159 patients from TRITON‐TIMI 38 was undertaken. A multilinear regression model was used to quantitatively predict…”
Get full text

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects by Jakubowski, Joseph A, Payne, Christopher D, Weerakkody, Govinda J, Brandt, John T, Farid, Nagy A, Li, Ying G, Naganuma, Hideo, Lachno, D Richard, Winters, Kenneth J

“…The aims of this open-label, randomized, dose-escalation pharmacodynamic study of prasugrel, an orally active antiplatelet agent, were to assess its…”
Get full text

Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort by Smith, Peter K., MD, Goodnough, Lawrence T., MD, Levy, Jerrold H., MD, Poston, Robert S., MD, Short, Mary A., MSN, Weerakkody, Govinda J., PhD, LeNarz, LeRoy A., MD

“…Objectives The objective of this study was to characterize the bleeding, transfusion, and other outcomes of patients related to the timing of prasugrel or…”
Get full text

Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis by Weerakkody, Govinda J, Jakubowski, Joseph A, Brandt, John T, Payne, Christopher D, Naganuma, Hideo, Winters, Kenneth J

“…Multiple studies report response variability to a 300-mg clopidogrel loading dose (LD). Pooled platelet aggregometry data compared responses (change in maximal…”
Get more information

Clopidogrel poor responders: An objective definition based on Bayesian classification by Weerakkody, Govinda J., Brandt, John T., Payne, Christopher D., Jakubowski, Joseph A., Naganuma, Hideo, Winters, Kenneth J.

“…Existing definitions of poor response to the antiplatelet effect of clopidogrel are empiric. Bayesian classification theory is widely used to classify subjects…”
Get full text

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial by Del Prato, Stefano, Pavo, Imre, Weerakkody, Govinda J, Yang, Zhengyu, Aizenberg, Diego, Wynne, Alan G, Wiese, Russell J, Arora, Samir, Calderon, Rafael B, Butuk, David J, Chaychi, Leila, Curtis, Brian M, Chochinov, Ronald, Chow, Christopher, Cone, Clancy L, Dungan, Kathleen, Gaudiani, Linda, Herandez-Vazquez, Luis, Hsia, Stanley H, Kutner, Mark E, Loy, Juan, Miranda, Francisco G, Oliver, Michael J, Parke, Michael T, Philis-Tsimikas, Athena, Rosenstock, Julio, Sorial, Ehab, Stonesifer, Larry D, Stringam, Stanley, Van, Joanna T, Vazquez-Tanus, Jose B, Reyes, Ramon, Karimjee, Najmuddin, Martin, Earl E, Fraser, Neil J, Bhargava, Anuj, Wynne, Alan G, Billings, Liana, Walsh, Patrick, Shubrook, Jay, Knouse, Albert B, Mayfield, Ronald K, Bitar, Fahed G, de la Cuesta, Carmen, Morales Portillo, Cristobal J, Quesada Charneco, Miguel, Tofe Povedano, Santiago, Vazquez, Luis, Soto Gonzalez, Alfonso, Ciomos, Daniela, Neacsu, Valentina, Stern, Naftali, Sofer, Yael, Sack, Jessica, Tirosh, Amir, Shehadeh, Naim, Darawsha, Mahmud, Skripova, Dasa, Pavleova, Eva, Kubincova, Ludmila, Merciakova, Martina, St-Amour, Eric, Yared, Zeina, Blouin, Francois, Aggarwal, Naresh K, Bajaj, Harpreet, Tailor, Chetna, Egan, Alan, St.Onge, Natasha, Borges, Joao L C, Franco, Denise R, Souza, Filipe D, Russo, Luis Augusto T, Sassone, Sonia A, Steinacher, Andrea, Perez Manghi, Federico C, Orio, Silvia I, Gelersztein, Elizabeth, Fretes, José O, Calella, Pedro R F, Zaidman, Cesar J, Chertkoff, Alejandro, Gonzalez Galvez, Guillermo, Calvo, Cesar G, Sowinski, Dariusz, Jozefowska, Malgorzata, Skokowska, Ewa, Modzelewska, Anna, Gilfillan, Christopher, Morbey, Claire, Kaur, Kamal, Kemp, Laurence, Shea, Antony J, Kunitsyna, Marina A, Ou, Horng-Yih, Chen, Jung-Fu, Hwu, Chii-Min, Doupis, John, Pagkalos, Emmanouil, Mouslech, Zadalla

“…We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus…”
Get full text